AgingResearch.NewsJoin free

Merck Healthcare KGaA, Darmstadt, Germany

Part of Merck KGaA

CompanyGermanyFounded 2018

ROR

Merck Healthcare KGaA, Darmstadt, Germany develops 2 assets, the furthest approved (Mirdametinib). Mostly small molecule acting on MAP2K2, MAP2K1 and CSF1R; based in Germany, founded in 2018.

2
Assets
Furthest stage
Approved
12
Trials
5
Signals

Pipeline

2

  • Mirdametinib

    Inhibits MEK1 and MEK2, reducing MAPK signaling and tumor growth.

    Approved, Small molecule, MAP2K2, MAP2K1, neurofibromatosis type 1 (Phase 2), plexiform neurofibroma (Phase 2)

  • pimicotinib

    Inhibits CSF1R signaling to reduce tumor-associated macrophage proliferation and survival.

    Phase 3, Small molecule, CSF1R, tenosynovial giant cell tumor

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms5
  • Trials16
  • Signals11
  • Similar companies6

Papers

Intelligence